Compare Asana Inc. (ASAN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs ResMed Inc. — how do they compare? Asana Inc. trades at $9.16 (market cap $2.13B), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 15.3× Asana Inc.'s market cap, and ResMed Inc. pays a 1.17% dividend while Asana Inc. pays none. Which is the better fit depends on your goals.
| ASAN | RMD | |
|---|---|---|
Market Cap | $2.13B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $293.73 |
52-Week Low | $5.46 | $182.82 |
Enterprise Value | $1.96B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.065, down 1.79% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is strong, reaching $723.88M in 2025, yet the company remains unprofitable with a net income margin of -20.21%. Recent earnings beats and AI product developments, including the StackAI acquisition, highlight operational momentum amid competitive pressures.
The outlook is mixed: analyst consensus leans neutral with a $10.33 price target, suggesting modest upside, but persistent losses and high valuation ratios pose risks. Key catalysts include continued AI integration and FedRAMP authorization, while decelerating revenue growth and competition from tech giants remain headwinds for shareholder value.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
